News Release
To view the PDF files, you will need Acrobat Reader. You can download Adobe Acrobat from Adobe's website.
- WAP-8294A2, A First-linei Anti-MRSA Pruduct Candidate: Exclusive license agreement for Korea (January 21, 2011)
- ARYS-01, An exclusive license agreement for India, Sri Lanka, Nepal and Bhutan (July 29, 2010)
- ARH-1029, An exclusive license agreement for Korea (May 13, 2010)
- WAP-8294A2, A First-line Anti-MRSA Product Candidate, Funded by NEDO (New Energy and Industrial Technology Development Organization) in Japan
- PPI Effect & Eradication of H. pylori: License agreement boosts development of novel therapy against Peptic Ulcer Disease (2009/1/28)
- Change of our company name (as of July 1st, 2007)
- Cystic Fibrosis: License agreement boosts development of therapy against lung infections(2007/12/19)
- ARYS Phase II press release (2006/12/5)
- aRigen Group Starts Phase ll Clinical Study of ARYS-01 (Sorivudine) Cream (2006/3/23)
- aRigen, Inc. Signs A Strategic Alliance Agreement with LG Life Sciences, Ltd. for the Exclusive Marketing and Sales of FACTIVE® in Japan (2005/9/30)
- Initiation of Clinical Studay of ARYS-01 Cream, a topical anti-herpes zoster drug, in the US (2005/5/25)
- ARYS-01 (JA-001) IND (2005/4/12)
- aRigen, Japanese Bioventure Company, Announces Start of US Clinical Study of Novel Anti-Staph Anti biotic (2004/9/15)
- Establishment of a Japan-US Joint Venture (2004/9/9)